Publication
Renal Function Decline After 177Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis.
Natasha Sheheryar, Yalda Nikanpour, Sandhya Manohar, Dan Childs, Gokce Belge Belgin, Robert McDonald, Jennifer McDonald, Matt P Thorpe, Geoffrey B Johnson
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
We conducted a study to determine the effects of 177Lu-PSMA-617 treatment on renal function decline in patients with metastatic castration-resistant prostate cancer (mCRPC) shortly after treatment and over long-term follow-up. Methods: The study used comparative and counterfactual analysis.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available